Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

[1] Whelton PK(2018)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines Hypertension 71 e13-e115

[2] Carey RM(2018)Potential U.S. population impact of the 2017 ACC/AHA high blood pressure guideline J Am Coll Cardiol 71 109-118

[3] Aronow WS(2014)Hypertension in the United States, 1999 to 2012: progress toward healthy people 2020 goals Circulation 130 1692-1699

[4] Casey DE(2012)Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010 Lancet 380 2163-2196

[5] Collins KJ(2002)Drugs targeting the renin-angiotensin-aldosterone system Nat Rev Drug Discov 1 621-636

[6] Dennison Himmelfarb C(1957)The preparation, purification, and amino acid sequence of a polypeptide renin substrate J Exp Med 106 439-453

[7] Muntner P(2010)Inhibition of the renin Angiotensin Aldosterone System: focus on Aliskiren JAPI 58 102-108

[8] Carey RM(2017)Blood pressure lowering efficacy of renin inhibitors for primary hypertension Cochrane Database Syst Rev 4 Cd007066-96

[9] Gidding S(2013)Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials Bmj 346 f360-1558

[10] Jones DW(2017)Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy J Renin-Angiotensin-Aldosterone Syst 18 1470320317729919-261

[1] Whelton PK(2018)2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines Hypertension 71 e13-e115

[2] Carey RM(2018)Potential U.S. population impact of the 2017 ACC/AHA high blood pressure guideline J Am Coll Cardiol 71 109-118

[3] Aronow WS(2014)Hypertension in the United States, 1999 to 2012: progress toward healthy people 2020 goals Circulation 130 1692-1699

[4] Casey DE(2012)Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010 Lancet 380 2163-2196

[5] Collins KJ(2002)Drugs targeting the renin-angiotensin-aldosterone system Nat Rev Drug Discov 1 621-636

[6] Dennison Himmelfarb C(1957)The preparation, purification, and amino acid sequence of a polypeptide renin substrate J Exp Med 106 439-453

[7] Muntner P(2010)Inhibition of the renin Angiotensin Aldosterone System: focus on Aliskiren JAPI 58 102-108

[8] Carey RM(2017)Blood pressure lowering efficacy of renin inhibitors for primary hypertension Cochrane Database Syst Rev 4 Cd007066-96

[9] Gidding S(2013)Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials Bmj 346 f360-1558

[10] Jones DW(2017)Plasma renin activity in patients with heart failure and reduced ejection fraction on optimal medical therapy J Renin-Angiotensin-Aldosterone Syst 18 1470320317729919-261